HSHaya Ayyal Salman

Haya Ayyal Salman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haya Ayyal Salman has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ephedra alte extracts' GC-MS profiles and antimicrobial activity against multidrug-resistant pathogens (MRSA)

    by Haya Ayyal Salman, Amira Suriaty Yaakop, Fuad Al-Rimawi, Ana Masara Ahmad Makhtar, Muath Mousa, Mohammad H. Semreen, Naiyf S. Alharbi


  • Open Access

    Drug Formulation of Securigera securidaca Seed Extracts

    by Mohamed E. M. Abdelbagi, Ghassab M. Al-Mazaideh, Adil Elhag Ahmed, Fuad Al-Rimawi, Haya Ayyal Salman, Abdulrahman Almutairi, Faraj Ahmad Abuilaiwi, Fadel Wedian

    S. securidaca seeds are reported to treat a variety of diseases; they contain multiple antidiabetic constituents and are widely used as anti-hyperglycemic, antibacterial, as well as anti-hyperlipidemic agents. The present work aimed to propose tablet formulations containing extracts of S. securidaca seeds in an attempt to obtain antibacterial and anti-hyperglycemic formulations with a more efficient oral hypoglycemic impact, limited side effects, and higher patient compliance for the first time, resulting in multiple benefits. Tablet formulations were created by encapsulating granules from S. securidaca seed extracts with varying concentrations of sodium starch glycolate as a super-disintegrant (0–3%). The final formulations were examined for weight variation, solubility, hardness, water content, disintegration time, friability, drug content (trigonelline and diosgenin), and in vitro drug release. The S. securidaca tablet formulations completed the weight test because the percentage deviation in the personal tablet weight and mechanical resistance from the mean were identified to be within the average range. In accordance with the results, formulations containing diosgenin as well as trigonelline as a super-disintegrant were identified as the ideal formulations. The amount of the active substance released from the tablet (S. securidaca seed extract formulation) was consistent throughout the results with the standard methods recommended by the FDA (94.05%) for diosgenin and 87.25% for trigonelline after 45 min. The acceptable limit, according to the FDA, is not more than (N.L.T.) 80% after 45 min for phase #1. The present study aimed to obtain an optimized formula for S. securidaca extract tablets that met the requirements of a good pharmaceutical preparation according to the United States Pharmacopeia (USP) and National Formulary (NF). This has important implications for the development of novel, effective treatments and significantly advances the development of natural medicine. Our findings are expected to be of interest to researchers, clinicians, and other experts in this field of study. Based on these findings, it can be inferred that the formulation of S. securidaca seed extracts with appropriate and compatible herbal dosage forms has fewer side effects and is more effective than traditional treatments.


  • Open Access

    Exploring Securigera securidaca Seeds as a Source of Potential CDK1 Inhibitors: Identification of Hippeastrine and Naringenin as Promising Hit Candidates

    by Mohamed E. M. Abdelbagi, Ghassab M. Al-Mazaideh, Adil Elhag Ahmed, Fuad Al-Rimawi, Haya Ayyal Salman, Abdulrahman Almutairi, Faraj Ahmad Abuilaiwi, Fadel Wedian

    CDK1 (cyclin dependent kinase 1) is a key regulator of the cell cycle and is frequently dysregulated in cancer, making it a promising target for anticancer therapy. Securigera securidaca L. (S. securidaca) seeds, traditionally used in folk medicine for various ailments including cancer, were examined for their potential as CDK1/Cks2 inhibitors using in silico approaches. A total of 14 phytocompounds was identified in the GC/MS chromatogram, with gingerone being the most abundant at 25.67% and hippeastrine the least at 2%. Major constituents of the essential extract, including gingerol, eugenol, α-curcumene, and gingerol, showed high values and made up 52% of the total content of the volatile extract. Molecular docking and ADMET studies suggested that hippeastrine and naringenin are potential hit candidates against CDK1, exhibiting good drug-like properties and molecular interactions with desirable pharmacokinetic and toxicological characteristics close to dinaciclib. Furthermore, molecular dynamics (MD) simulations showed that both compounds exhibited stable conformations inside the binding site over the 100 ns MD simulation, suggesting they may stabilize the protein structure by reducing the flexibility of the CDK1 backbone. Additionally, MM-PBSA calculations further supported the stability of hippeastrine and naringenin in CDK1 complexes. Overall, these findings suggest that hippeastrine and naringenin are potential hit candidates for CDK1 inhibition, providing valuable insight into their binding and stability within the active site of CDK1. Further investigation of these compounds with in vitro and in vivo assays is warranted to assess their potential as CDK1 inhibitors for cancer therapy.